Here’s what you need to know:
1. Two-thirds of patients treated with Kanuma for 52 weeks experienced reduced liver fibrosis.
2. Half of patients treated with Kanuma for 52 weeks experienced at least a two-stage reduction in liver fibrosis.
3. Kanuma-treated patients also experienced improvements in alanine aminotransferase, LDL cholesterol and liver fat content.
More articles on gastroenterology and endoscopy:
Takeda Pharmaceutical, New York Academy of Sciences establish $200k research prize: 3 notes
Clinical Genomics’ circulating tumor DNA blood test proves effective for CRC recurrence detection: 3 notes
AGA, NACCME develop 3 regional educational programs about IBD: 3 notes
